GRALGRAIL, Inc.
Price
+255%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality mixed, hard red flags, growing in the filings, the market undecided.
We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.
In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
GRAIL, Inc. (GRAL) reported revenue of $45M in Q2 2026 (quarter ended Jun 30, 2026), up 26% from the same quarter a year earlier. That came with net loss of $110M. For the full year FY2025, revenue was $147M (+17% year on year) and net income −$408M. Its largest region in Q2 2026 was United States at $41M, 97% of the disclosed total, well ahead of Non Us at 2.8%. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026GRAIL Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jun 1, 2026In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended …Director or officer change · Form 8-K
- Feb 19, 2026On February 19, 2026, the Company also issued a press release announcing top-line results from its NHS-Galleri trial, a randomized controlled trial conducted in partnership with NHS England, showing that, although the primary endpoint of statistically significant Stage III-IV reduction was not observed, adding …Earnings release · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $42.6MThe company’s own SEC segment disclosure.
- United States$41.4M97%
- Non Us$1.2M3%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #15 of 21 by RyuScore